探索精神分裂症及其药物治疗对健康相关生活质量和治疗偏好的影响。
Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences.
作者信息
Arango Celso, Baeza Inmaculada, García-Rizo Clemente, Crespo-Facorro Benedicto, Lahera Guillermo, Vieta Eduard, Becker Frauke, Dwyer Georges, Bourke Siobhan, Gibson Adam E J, Gabarda-Inat Irene, Alvarez-Baron Elena
机构信息
Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, CIBERSAM, IiSGM, Universidad Complutense, School of Medicine, Madrid, Spain.
Department of Child and Adolescent Psychiatry and Psychology, 2021SGR01319, Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM; Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain.
出版信息
Patient Prefer Adherence. 2025 Aug 27;19:2647-2661. doi: 10.2147/PPA.S494721. eCollection 2025.
PURPOSE
Pharmacological treatments play an important role in managing symptoms of schizophrenia but can also be associated with side effects. The aim of this study was to understand the impact of schizophrenia and its pharmacological treatment on patients' health-related quality of life (HRQoL) and to explore patient preferences around treatment benefits and side effects.
PATIENTS AND METHODS
This study employed a mixed methods approach with two stages of recruitment of adult patients in Spain. Stage 1 included qualitative and quantitative elements (including included two validated patient-reported outcome measures: PETiT and EQ-5D-5L) administered in telephone interviews with people with schizophrenia. Stage 2 consisted of a quantitative online survey completed by people with schizophrenia attending outpatient clinics. Responses to quantitative items across both stages were combined for analysis.
RESULTS
Twenty respondents completed the mixed methods interviews (stage 1), and 25 participants completed the online survey (stage 2). Results from stages 1 and 2, showed that participants perceived treatments to have a beneficial impact on controlling their symptoms. However, cognitive side effects were reported to have a detrimental impact on respondents' daily life and were considered a primary reason for treatment cessation in the past. Qualitative findings further showed that most participants hoped future treatments would minimise the impact of cognitive symptoms of schizophrenia.
CONCLUSION
The findings suggest that patients' expectation around treatment efficacy and their acceptability of treatment side effects may indicate their capacity to maintain long-term treatment adherence. Trade-offs that patients may be willing to make between these components may prove useful to consider in clinical practice to improve treatment adherence and hence treatment effectiveness in people with schizophrenia.
目的
药物治疗在精神分裂症症状管理中发挥着重要作用，但也可能伴有副作用。本研究的目的是了解精神分裂症及其药物治疗对患者健康相关生活质量（HRQoL）的影响，并探索患者对治疗益处和副作用的偏好。
患者与方法
本研究采用混合方法，分两个阶段招募西班牙成年患者。第一阶段包括定性和定量元素（包括两项经过验证的患者报告结局指标：PETiT和EQ-5D-5L），通过电话访谈对精神分裂症患者进行评估。第二阶段包括由门诊精神分裂症患者完成的定量在线调查。将两个阶段对定量项目的回答合并进行分析。
结果
20名受访者完成了混合方法访谈（第一阶段），25名参与者完成了在线调查（第二阶段）。第一阶段和第二阶段的结果表明，参与者认为治疗对控制症状有有益影响。然而，据报告认知副作用对受访者的日常生活有不利影响，并且被认为是过去治疗中断的主要原因。定性研究结果进一步表明，大多数参与者希望未来的治疗能够将精神分裂症认知症状的影响降至最低。
结论
研究结果表明，患者对治疗效果的期望及其对治疗副作用的可接受性可能表明他们维持长期治疗依从性的能力。患者在这些因素之间可能愿意做出的权衡，在临床实践中考虑可能有助于提高治疗依从性，从而提高精神分裂症患者的治疗效果。
Zotero 插件